Sökresultat
90% av patienterna överlevde 5 år med Calquence + obinutuzumab vid KLL
…survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for Calquence at a median follow up of approximately five years in combination and as a monotherapy in chronic lymphocytic leukaemia (CLL).1 Results also showed longer overall survival (OS) for Calquence combined with obinutuzumab compared with chlorambucil combined with obinutuzumab in previously untreated adults w…
Astra Zenecas Lynparza minskade sjukdomsprogression och dödsfall vid prostatacancer
…te cancer is often driven by male sex hormones called androgens, including testosterone.9 In patients with mCRPC, their prostate cancer grows and spreads to other parts of the body despite the use of androgen-deprivation therapy to block the action of male sex hormones.10 Approximately 10-20% of patients with advanced prostate cancer will develop castration-resistant prostate cancer (CRPC) within five years, and at least 84% of these patients will…
Lynparza rekommenderas i EU för adjuvant behandling av HER2-negativ tidig bröstcancer
…BRCA-mutated HER2-negative high-risk early breast cancer First PARP inhibitor to improve overall survival in early-stage breast cancer. AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) who have HER2-negative high-risk early breast cancer p…
Rozlytrek godkändes i Europa för patienter med NTRK fusion-positiva solida tumörer samt för patienter med ROS1-positiv avancerad icke småcellig lungcancer
…e most common genetic drivers of lung cancer or to boost the immune system to combat the disease. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche…
Enhertu rekommenderas i EU vid HER2-positiv metastaserad bröstcancer
…neered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast03 Phase III trial, which were published in The New England Journal of Medicine.1 In the trial, Enhertu reduced the risk of disease progression or death by 72% vers…